TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28763408

Group type: EXPERIMENTAL
Intervention: Work-family conflict intervention
Number of subjects: 0
Study: 26023227

Group type: EXPERIMENTAL
Intervention: l-Citrulline (6 g/day)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: l-Arginine (6 g/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 23473847

Group type: EXPERIMENTAL
Intervention: Clinically driven monitoring
Number of subjects: 1206

Group type: COMPARATOR
Intervention: Routine laboratory monitoring
Number of subjects: 1206

Group type: EXPERIMENTAL
Intervention: Three-drug ART (NNRTI, lamivudine, abacavir)
Number of subjects: 1206

Group type: EXPERIMENTAL
Intervention: Four-drug ART (NNRTI, lamivudine, abacavir, zidovudine)
Number of subjects: 1206
Study: 22036246

Group type: EXPERIMENTAL
Intervention: Insulin lispro mix 50/50 (TID group)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Insulin lispro mix 75/25 or biphasic insulin aspart 70/30 (BID group)
Number of subjects: 302
Study: 17985194

Group type: EXPERIMENTAL
Intervention: Group-based exercise programme
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Home-based exercise programme
Number of subjects: 41
Study: 16846551

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Number of subjects: 6743

Group type: COMPARATOR
Intervention: Atorvastatin 10 mg
Number of subjects: 6743

Group type: COMPARATOR
Intervention: Simvastatin 20 mg
Number of subjects: 6743
Study: 15670201

Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg daily (n = 12)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg twice weekly (n = 11)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo daily (n = 14)
Number of subjects: 37
Study: 11930855

Group type: EXPERIMENTAL
Intervention: Nurse practitioner care
Number of subjects: 79
Study: 9480230

Group type: EXPERIMENTAL
Intervention: Camit-Diacomp system
Number of subjects: 2

Group type: COMPARATOR
Intervention: Standard insulin treatment without Camit-Diacomp system
Number of subjects: 2
Study: 8173753

Group type: EXPERIMENTAL
Intervention: Inhaled PGE2
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 3294920

Group type: EXPERIMENTAL
Intervention: Tiaspirone, treated for 28 days
Number of subjects: 14
Study: 31893985

Group type: EXPERIMENTAL
Intervention: Left atrial enlargement
Number of subjects: 3983

Group type: EXPERIMENTAL
Intervention: Ipsilateral plaque
Number of subjects: 3983

Group type: EXPERIMENTAL
Intervention: Both left atrial enlargement and ipsilateral plaque
Number of subjects: 3983

Group type: EXPERIMENTAL
Intervention: Association between left atrial dimension and ipsilateral plaque
Number of subjects: 3983

Group type: EXPERIMENTAL
Intervention: Secondary markers of atrial cardiopathy
Number of subjects: 3983
Study: 29618162

Group type: EXPERIMENTAL
Intervention: Tinzaparin (175 IU/kg once daily)
Number of subjects: 864

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 864
Study: 26805417

Group type: EXPERIMENTAL
Intervention: 4‐t‐butylcyclohexanol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Licochalcone A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formulation containing 4‐t‐butylcyclohexanol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cream base containing 4‐t‐butylcyclohexanol and licochalcone A
Number of subjects: 0
Study: 24726785

Group type: EXPERIMENTAL
Intervention: ESMI group
Number of subjects: 196
Study: 23128469

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (2,000 IU once daily for 12 weeks)
Number of subjects: 36
Study: 20795425

Group type: EXPERIMENTAL
Intervention: 15 mL fish oil daily (550 mg eicosapentaenoic acid; 205 mg decosahexaenoic acid)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 15 mL fish oil daily
Number of subjects: 36
Study: 18834296

Group type: EXPERIMENTAL
Intervention: Reintegration training program
Number of subjects: 128

Group type: COMPARATOR
Intervention: Booster sessions
Number of subjects: 128
Study: 17058827

Group type: EXPERIMENTAL
Intervention: Routine CHD plus Salvia miltiorrhiza (SM)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Routine CHD
Number of subjects: 36

Group type: COMPARATOR
Intervention: Normal control (healthy adults)
Number of subjects: 36
Study: 12826985

Group type: EXPERIMENTAL
Intervention: bupropion (150 mg) once daily
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: bupropion (300 mg)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: methylphenidate SR (20 mg daily)
Number of subjects: 25

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 25
Study: 11256129

Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia using Propofol/Sufentanil (TIVA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Balanced inhalational anaesthesia using Trapanal/Sevoflurane (BIA)
Number of subjects: 0
Study: 9006528

Group type: EXPERIMENTAL
Intervention: 7‐mg/kg cefdinir, twice daily, for 5 days
Number of subjects: 440

Group type: COMPARATOR
Intervention: 10‐mg/kg penicillin V potassium, 4 times daily, for 10 days
Number of subjects: 440
Study: 8314358

Group type: EXPERIMENTAL
Intervention: cilazapril (5 mg o.d.)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: atenolol (100 mg o.d.)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 16
Study: 3475771

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 31815684

Group type: EXPERIMENTAL
Intervention: Dry Needling (DN)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Ischemic Compression (IC)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control
Number of subjects: 29
Study: 30539289

Group type: EXPERIMENTAL
Intervention: 1100F/HMPnano
Number of subjects: 12

Group type: COMPARATOR
Intervention: 1100F
Number of subjects: 12
Study: 27440250

Group type: EXPERIMENTAL
Intervention: Exploring Feelings CBT intervention (n=18)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Wait-list control group (n=17)
Number of subjects: 35
Study: 25336623

Group type: EXPERIMENTAL
Intervention: GM-PCR group (serum GM and PCR assays results provided)
Number of subjects: 219

Group type: COMPARATOR
Intervention: GM group (only serum GM results informed)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: GM-PCR group
Number of subjects: 219

Group type: COMPARATOR
Intervention: GM group
Number of subjects: 219
Study: 23204220

Group type: EXPERIMENTAL
Intervention: Oral cholecalciferol 2000 IU/day
Number of subjects: 267

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study: 21543930

Group type: EXPERIMENTAL
Intervention: Routine follow-up visits (more than recommended)
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Asymptomatic detection at routine visit
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Symptomatic detection at routine visit
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Diagnosis after an interval visit
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Detection method comparison
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Time from primary treatment to recurrence
Number of subjects: 579
Study: 19405756

Group type: EXPERIMENTAL
Intervention: Commercial sunscreens characterized by USPF
Number of subjects: 0

Group type: COMPARATOR
Intervention: USPF obtained for human skin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Porcine skin
Number of subjects: 0
Study: 17715049

Group type: EXPERIMENTAL
Intervention: Propofol target controlled infusion (TCI)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sevoflurane inhalational anesthesia
Number of subjects: 60
Study: 15549974

Group type: EXPERIMENTAL
Intervention: Propofol‐Lipuro
Number of subjects: 200

Group type: COMPARATOR
Intervention: Diprivan mixed with lidocaine 10 mg
Number of subjects: 200
Study: 11911312

Group type: EXPERIMENTAL
Intervention: 5-FU intravenous injection at 1000 mg/m2 body surface area/24 hours for 72 hours + oral HCFU 300 mg daily for 52 weeks (Group B)
Number of subjects: 314

Group type: COMPARATOR
Intervention: 5-FU intravenous injection at 333 mg/m2 body surface area/24 hours for 72 hours + oral HCFU 300 mg daily for 52 weeks (Group A)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 314
Study: 9855228

Group type: EXPERIMENTAL
Intervention: Boneloc bone cement
Number of subjects: 19

Group type: COMPARATOR
Intervention: Palacos bone cement
Number of subjects: 19
Study: 7889236

Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 0
Study: 2493100

Group type: EXPERIMENTAL
Intervention: 2% nitroglycerin paste
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo ointment base
Number of subjects: 26
Study: 31974753

Group type: EXPERIMENTAL
Intervention: CO2 laser moxibustion
Number of subjects: 392

Group type: COMPARATOR
Intervention: Sham laser moxibustion
Number of subjects: 392
Study: 31243778

Group type: EXPERIMENTAL
Intervention: HALTHCC risk score (preoperatively calculated continuous risk score)
Number of subjects: 4089

Group type: EXPERIMENTAL
Intervention: HALTHCC score before recalibration
Number of subjects: 4089

Group type: EXPERIMENTAL
Intervention: HALTHCC score after recalibration
Number of subjects: 4089
Study: 28853303

Group type: EXPERIMENTAL
Intervention: DASHNa‐CC intervention (Dietary Approach to Stop Hypertension With Sodium Reduction for Chinese Canadian)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: DASHNa‐CC intervention
Number of subjects: 60
Study: 26074293

Group type: EXPERIMENTAL
Intervention: Desarda repair
Number of subjects: 168

Group type: COMPARATOR
Intervention: Lichtenstein repair
Number of subjects: 168
Study: 23562009

Group type: EXPERIMENTAL
Intervention: Daclizumab HYP 150 mg
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: Daclizumab HYP 300 mg
Number of subjects: 621

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 621
Study: 21796092

Group type: EXPERIMENTAL
Intervention: PEVAR with adjunctive 'pre-close' techniques using ProGlide or Prostar XL devices
Number of subjects: 38
Study: 19921354

Group type: EXPERIMENTAL
Intervention: Landiolol infusion (0.125 mg kg(‐1) min(‐1) for 1 min, then 0.04 mg kg(‐1) min(‐1) until extubation)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Landiolol infusion
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control (saline infusion)
Number of subjects: 63
Study: 16963585

Group type: EXPERIMENTAL
Intervention: Pharmacologic antidepressant treatment
Number of subjects: 59

Group type: COMPARATOR
Intervention: Psychotherapy conditions
Number of subjects: 59
Study: 15673949

Group type: EXPERIMENTAL
Intervention: Piroxicam 20 mg/day for 3 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Meloxicam 15 mg/day for 3 weeks
Number of subjects: 20
Study: 11732147

Group type: EXPERIMENTAL
Intervention: Oral prednisone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-steroid treatment
Number of subjects: 0
Study: 9129961

Group type: EXPERIMENTAL
Intervention: U.S. blacks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nigerians
Number of subjects: 0
Study: 8722923

Group type: EXPERIMENTAL
Intervention: Derived 12-lead electrocardiogram
Number of subjects: 250

Group type: COMPARATOR
Intervention: Routine monitoring of leads V1 and II
Number of subjects: 250
Study: 2265331

Group type: EXPERIMENTAL
Intervention: Intravenous indomethacin
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Intramuscular diclofenac
Number of subjects: 145

Group type: COMPARATOR
Intervention: Intravenous Avafortan
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Second dose of prostaglandin synthetase inhibitors
Number of subjects: 145
Study: 6445225

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide and 5-Fluorouracil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estramustine phosphate and streptozotocin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prednimustine and imidazole carboxamide (DTIC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DES combined with cyclophosphamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methyl-CCNU and hydroxyurea
Number of subjects: 0

Group type: COMPARATOR
Intervention: Estramustine phosphate and vincristine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclophosphamide and estramustine phosphate
Number of subjects: 0
Study: 31120555

Group type: EXPERIMENTAL
Intervention: Peanut allergy (PNA) diagnosis
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: Univariate factors associated with PNA
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: Multivariate model
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: Models using stricter or less strict PNA criteria
Number of subjects: 511
Study: 28288302

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle warm-up (IMW) comprising 2 × 30 inspiratory efforts against a pressure-threshold load of 40% maximal inspiratory pressure (PImax)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 10-min unloaded running (AWU) at lactate turnpoint (10.33 ± 1.58 km·h‐1)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo inspiratory muscle warm-up (PLA) comprising 5-min breathing using a sham device
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: AWU+IMW
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: AWU+PLA
Number of subjects: 9
Study: 26341820

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Brief support (monthly weigh-ins and meeting)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: App (use of MyFitnessPal with limited support)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Daily self-weighing (with brief monthly feedback)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Hunger training (four-week programme which trains individuals to only eat when physically hungry)
Number of subjects: 250
Study: 24947922

Group type: EXPERIMENTAL
Intervention: Personal material that was strictly healthy
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Solely professional material
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Personal material that included unhealthy behavior
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Female profiles
Number of subjects: 250
Study: 22668675

Group type: EXPERIMENTAL
Intervention: Meaningful task-specific training (MTST)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Standard training
Number of subjects: 103
Study: 20430112

Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drugs (AAD)
Number of subjects: 1400

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 1400

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 1400

Group type: EXPERIMENTAL
Intervention: Rate-controlling medications
Number of subjects: 1400

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 1400

Group type: EXPERIMENTAL
Intervention: Calcium channel blockers
Number of subjects: 1400
Study: 17494791

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Not applicable (control group)
Number of subjects: 24
Study: 15714841

Group type: EXPERIMENTAL
Intervention: Parent management training
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (medication with methylphenidate plus consultation)
Number of subjects: 33
Study: 12046876

Group type: EXPERIMENTAL
Intervention: Wavefront-guided customized ablation
Number of subjects: 11

Group type: COMPARATOR
Intervention: Conventional ablation
Number of subjects: 11
Study: 10405869

Group type: EXPERIMENTAL
Intervention: Twice a year deworming with single dose mebendazole
Number of subjects: 3028

Group type: EXPERIMENTAL
Intervention: Three times a year deworming
Number of subjects: 3028

Group type: COMPARATOR
Intervention: Control group (no deworming)
Number of subjects: 3028
Study: 8839508

Group type: EXPERIMENTAL
Intervention: Glutamine-enriched feeding
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard peptide-based feeding (control)
Number of subjects: 28
Study: 1636398

Group type: EXPERIMENTAL
Intervention: Tear thinning time
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Schirmer tear test
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Classification of dry eyes
Number of subjects: 34
Study: 6609807

Group type: EXPERIMENTAL
Intervention: Electrostimulation (ES)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral methadone
Number of subjects: 0
Study: 31595044

Group type: EXPERIMENTAL
Intervention: 177Lu‐DOTA‐PSMA‐617 (177Lu‐PSMA‐617)
Number of subjects: 0
Study: 31806610

Group type: EXPERIMENTAL
Intervention: Replacing the nail plate after nail bed repair
Number of subjects: 416

Group type: COMPARATOR
Intervention: Discarding the nail plate after nail bed repair
Number of subjects: 416
Study: 28595839

Group type: EXPERIMENTAL
Intervention: Piezosurgery (group I)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional osteotomy (group II)
Number of subjects: 50
Study: 26364905

Group type: EXPERIMENTAL
Intervention: Target oxygen saturation of ≥ 90% (modified care)
Number of subjects: 615

Group type: COMPARATOR
Intervention: Target oxygen saturation of ≥ 94% (standard care)
Number of subjects: 615
Study: 23648788

Group type: EXPERIMENTAL
Intervention: ARF-1 (nonhydrolyzed protein, locust bean gum)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: ARF-2 (specific whey hydrolysate, locust bean gum, specially treated starch)
Number of subjects: 115

Group type: COMPARATOR
Intervention: ARF-1
Number of subjects: 115
Study: 21858008

Group type: EXPERIMENTAL
Intervention: Cervicovaginal lavage (CVL) with Normosol-R (n=20)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cervicovaginal lavage (CVL) with saline (n=14)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cervicovaginal lavage (CVL) with water (n=14)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Endocervical swabs
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Endocervical and vaginal flocked swabs
Number of subjects: 48

Group type: COMPARATOR
Intervention: Dacron swabs
Number of subjects: 48
Study: 19700413

Group type: EXPERIMENTAL
Intervention: Cryotherapy and podophyllotoxin 0.15% cream
Number of subjects: 140

Group type: COMPARATOR
Intervention: Cryotherapy alone
Number of subjects: 140
Study: 17933157

Group type: EXPERIMENTAL
Intervention: 1 mg of risperidone
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 15292666

Group type: EXPERIMENTAL
Intervention: Hypericum extract LI160 (300 mg twice a day for 2 weeks)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 11148433

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 8262685

Group type: EXPERIMENTAL
Intervention: Nicotine transdermal therapeutic system (TTS)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo transdermal therapeutic system (TTS)
Number of subjects: 160
Study: 3898725

Group type: EXPERIMENTAL
Intervention: Citalopram (20-80 mg, most frequently 40 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Mianserin (60-120 mg, most frequently 90 mg)
Number of subjects: 60
Study: 31877377

Group type: EXPERIMENTAL
Intervention: Real needles
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham needles
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Blindfolded condition
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sighted condition
Number of subjects: 40
Study: 29283682

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula oxygen therapy plus long-term oxygen therapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Long-term oxygen therapy only
Number of subjects: 32
Study: 27422271

Group type: EXPERIMENTAL
Intervention: Supported Employment (SE)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Traditional Vocational Rehabilitation (TVR)
Number of subjects: 124
Study: 24969592

Group type: EXPERIMENTAL
Intervention: Helioseal F, a light-cured resin-based sealant
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: FUJI VII, a light-cured glass ionomer sealant
Number of subjects: 419

Group type: COMPARATOR
Intervention: Blank control
Number of subjects: 419
Study: 23412098

Group type: EXPERIMENTAL
Intervention: Gemcitabine + 400 mg upamostat (arm C)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Gemcitabine + 200 mg upamostat (arm B)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Gemcitabine alone (arm A)
Number of subjects: 95
Study: 20456590

Group type: EXPERIMENTAL
Intervention: Nutrition and lifestyle interventions
Number of subjects: 0
Study: 18565142

Group type: EXPERIMENTAL
Intervention: ProSymbioflor (an autolysate of cells and cell fragments of Enterococcus faecalis and Escherichia coli)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 297
Study: 16641530

Group type: EXPERIMENTAL
Intervention: Epidural continuous infusion without an initial dose (continuous group)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Epidural continuous infusion with an initial dose (initial dose group)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Spinal anesthesia (spinal group)
Number of subjects: 61
Study: 12731612

Group type: EXPERIMENTAL
Intervention: Carisolv
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional drilling
Number of subjects: 45
Study: 11050836

Group type: EXPERIMENTAL
Intervention: Cefuroxime 750 mg t.i.d, i.v.
Number of subjects: 101

Group type: COMPARATOR
Intervention: Cephradine 1 g q.i.d., i.v.
Number of subjects: 101
Study: 8617907

Group type: EXPERIMENTAL
Intervention: Exercise for 60 minutes twice a week for 6 months
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no specific exercise regimen)
Number of subjects: 42
Study: 1320536

Group type: EXPERIMENTAL
Intervention: 1.75% delta‐9‐tetrahydrocannabinol
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 3.55% delta‐9‐tetrahydrocannabinol
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 1.75% and 3.55% delta‐9‐tetrahydrocannabinol
Number of subjects: 6
Study: 3776752

Group type: EXPERIMENTAL
Intervention: Medical intervention (study group)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 174
Study: 30301475

Group type: EXPERIMENTAL
Intervention: EndoSuture Trainer Box Simulator (ESTBS)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard Laparoscopic Trainer (SLT)
Number of subjects: 37
Study: 28033399

Group type: EXPERIMENTAL
Intervention: Schroth physiotherapeutic scoliosis-specific exercises (PSSE)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 50